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rior to DTIC alone (OR = 1.40, CI95%:1.10–1.79). Non-
interferons were ineffective (OR = 1.24, CI95%:0.93–1.65).
Interferons appeared to be effective adjunctive therapies (OR =
1.60, CI95%:1.03–2.50) with a survival of 10.5 ± 4.2 months.
However, small (older) studies produced high rates while large
(newer) studies found lower rates. CONCLUSIONS: Meta
analysis of current publications demonstrated that standard
treatment with DTIC produces response rates between 12.6 and
17.2. The addition of other treatments to DTIC offer no clinical
advantage, except possibly interferons, but incremental advan-
tages are modest at best. Studies were generally of poor quality.
Effective treatments are needed to treat advanced melanoma.
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OBJECTIVE: The aim of the present study was to develop a
patient reported outcome (PRO) instrument which would be
suitable for use in clinical practice to measure the intensity and
impact of cancer-related fatigue (CRF), as well as patients’ atti-
tudes and beliefs regarding the condition. METHODS: Ques-
tionnaire content was generated from literature review, focus
groups with oncology patients, and expert meetings with oncol-
ogists and specialists in the production of PRO instruments.
Potential items were administered to oncology patients with CRF
in a multi-center, cross-sectional, item reduction study. Patients
answered all items twice to obtain data on both item frequency
and importance using 5-point Likert-type scales. Item reduction
was performed using a combination of clinimetric (calculation
of impact score by multiplying frequency and importance scores
for each item, expert opinion) and psychometric analysis (factor
analysis, evaluation of scale internal consistency), and Item
Response Theory (IRT) techniques. RESULTS: The initial pool
of 75 items was administered to 238 cancer patients (mean age
57 years, 56% women, 30% breast cancer, 64% with metasta-
sis, 46% with anemia). The 35 items with the lowest impact
score were eliminated in clinimetric analysis; statistical analyses
eliminated a further 15 items, and 13 items were eliminated on
the basis of expert clinical opinion, supported by ﬁndings from
the IRT analysis and item-scale correlations. The ﬁnal measure
includes 12 items. Factor analysis conﬁrmed the presence of 3
dimensions: physical function (4 items), activities daily living (4
items) and beliefs/attitudes (4 items). Cronbach’s alpha values for
the overall score and individual dimensions were 0.92, 0.78,
0.85, and 0.81, respectively. CONCLUSIONS: The combination
of methods for item reduction has led to the production of a new
instrument with 12 items and 3 dimensions, which it is hoped
will be suitable to measure aspects of CRF which are important
in clinical practice.
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OBJECTIVE: A PE analysis was performed to support the reim-
bursement request of erlotinib in 2nd/3rd-line treatment of
NSCLC in The Netherlands (NL). METHODS: Erlotinib and
BSC efﬁcacy data (based on the erlotinib registration study,
BR.21) were used for this analysis. Chart reviews (n = 96) were
conducted to obtain insight into health care utilisation (HCU) of
stage IIIB/IV relapsed NSCLC. Charts from patients treated with
docetaxel (n = 24) and BSC (n = 72) in 4 general and 1 acade-
mic hospital were used. The PE analysis was performed from the
societal perspective and both outcomes and efﬁcacy results were
discounted at 4%. Ofﬁcial price lists (2004) were used and the
price of erlotinib was set at €2184/150 mg/30 tablets. PE out-
comes extrapolated to 3 years were evaluated using a Markov
health-state model, adapted for NL. Outcomes and model
assumptions were approved by an expert panel of 10 Dutch clin-
icians. RESULTS: The average treatment costs per patient in NL
were €24,939 for docetaxel, €23,436 for erlotinib, and €15,450
for BSC. Life-years gained (LYG) were 0.84 years for docetaxel
and erlotinib and 0.62 years for BSC, as per the BR.21 registra-
tion trial intent-to-treat population. The incremental cost-
effectiveness ratio (ICER) for erlotinib vs BSC was €37,059/LYG
(CI €12,621–€72,960) based on 4.3 month treatment duration.
Erlotinib dominated docetaxel in all scenarios except when an
unrealistically low docetaxel dose (110mg/cycle) was assumed.
ICERs were sensitive to variations in length/frequency of hospi-
talizations and number of outpatient visits, illustrating the eco-
nomic impact of erlotinib’s generally mild adverse event proﬁle.
Erlotinib was cost-effective vs BSC in 80% of cases using a will-
ingness-to-pay (WTP) threshold of €50,000/LYG. CONCLU-
SIONS: Treatment with erlotinib dominates docetaxel and is
cost-effective vs BSC in NL. Based on the clinical efﬁcacy and
cost-effectiveness, erlotinib has received unrestricted reimburse-
ment for relapsed NSCLC in NL without requirements for
patient stratiﬁcation.
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OBJECTIVE: To evaluate the cost-effectiveness of erlotinib com-
pared to docetaxel for treating stage III/IV relapsed NSCLC from
the UK NHS’s perspective. METHODS: A cost-utility approach
was taken; primary endpoint was cost per QALY. Baseline
patient characteristics were based on trials BR.21 (erlotinib arm)
and TAX317 (docetaxel arm). Equivalent overall survival was
assumed; any bias from this assumption was expected to favour
docetaxel. The model stratiﬁed patients into progression-free
survival (PFS), progression and death. Time in each health state
was adjusted for QoL (EQ-5D data), including the impact of
adverse events (AEs) and formulation of therapy experienced in
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PFS. Monthly resource utilisation associated with PFS and pro-
gression was estimated by a consensus panel of UK experts. Cost
of AEs and drug-administration costs were also included. The
evaluation accounted for longer treatment duration (24%) with
erlotinib compared to docetaxel (mean duration 125 vs. 101
days, respectively). The incremental drug acquisition cost for
erlotinib vs docetaxel was consequently £1867. The primary
outcome was total direct NHS costs and QALYs. RESULTS:
Total direct NHS costs were £12,701 and £12,621 for erlotinib
and docetaxel, respectively. Erlotinib vs docetaxel offers a cost
saving of £971/patient due to its oral administration and
£301/patient in the management of AEs. QALYs were 0.201 
and 0.176 (erlotinib vs docetaxel, respectively). The ICER for
erlotinib vs docetaxel was estimated at £3354. Erlotinib was
cost-effective whether or not the calculation assumed improve-
ments in PFS. Improvements in QoL and reduced toxicity with
erlotinib led to greater total QALYs vs docetaxel. CONCLU-
SIONS: Erlotinib is a valuable alternative to docetaxel in
relapsed NSCLC. Efﬁcacious without compromising QoL and
well tolerated, erlotinib can be considered a highly cost-effective
treatment for NSCLC in the UK. Orally administered, it may also
be associated with a capacity beneﬁt to the NHS through reduc-
tion in existing infusion and outpatient requirements.
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OBJECTIVES: The large availability of economic evaluations
and their increasing importance for decision making emphasizes
the need for economic evaluations that are methodologically
sound. The aim of this study is to provide users of economic
evaluations of cholesterol lowering drugs with an insight into the
quality these evaluations. By focussing on the most relevant
studies the gap between research and policy making may be nar-
rowed. METHODS: A systematic review was conducted. All
publications on economic evaluations of cholesterol lowering
drugs were identiﬁed by searching Pub Med, the Centre for
Reviews and Dissemination database (CRD), the National
Health Service Economic Evaluation Database (NHS EED), the
Health Technology Assessment database (HTA) and the Data-
base of Abstracts of Reviews of Effects (DARE). A search strat-
egy was set up to identify the articles to be included. These
articles were quality assessed using Drummond’s checklists. The
scoring was performed by at least two reviewers. When neces-
sary, disagreement between these reviewers was decided upon in
a consensus meeting. We calculated an average quality score for
the included articles. RESULTS: The search identiﬁed 23 articles
that were included. Most studies measured the costs/LYG. The
overall score per study varied between 2.7 and 7.7 with an
average of 5.4. Most studies score high on the measurement of
costs and consequences whereas the establishment of effective-
ness leaves room for improvement. Only two studies included a
well performed incremental analysis. CONCLUSION: This
review noticed an increase of quality of economic evaluations
over time. Consequently, the value of cost-effectiveness studies
for policy decisions increases over time. In general piggy back
evaluations tend to score higher on quality and are therefore
more valuable in decisionmaking.
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OBJECTIVES: ARBs were introduced into the UK antihyper-
tensive drug market with conﬂicting data on their relative effec-
tiveness compared to other classes, which offered lower cost
alternatives. The study aim was to determine patient-level char-
acteristics of ARB prescribing patterns and how these changed
over time since the ﬁrst ARB market launch December 1994.
METHODS: The study population was identiﬁed from the
Health Improvement Network (THIN) database, an electronic
medical record dataset of patients seen by general practitioners
in the UK. Patients who received an oral drug approved for
hypertension treatment at any point in time from 1995 through
2003 were included. The multinomial logit model was applied
to two time periods to predict the likelihood of receiving an ARB
prescription compared to other antihypertensive drug classes,
after controlling for patient characteristics. A time dummy tested
for changes between the time periods. RESULTS: Immediately
after the ﬁrst ARB introduction (1995–1997), 0.25% (N =
537,309) of the study population was allocated to ARB therapy.
This rose to 6.22% (N = 803,981) for the more recent time
period (2001–2003). In the early time period, patients with high
blood pressure readings and patients seen by a Cardiologist were
more likely to receive prescriptions for ARBs than other antihy-
pertensive classes. This did not persist for the more recent time
period. Over time, prescribing antihypertensive drugs for
patients with diabetes shifted away from all classes (P < 0.01),
except the angiotensin converting enzyme inhibitor (ACEi) class
(P = 0.6334), towards ARB prescribing. For patients with heart
failure, there was a statistically signiﬁcantly shift away from pre-
scribing ARBs towards the beta-blocker and “Other” classes. In
general, patients with diabetes or heart failure were more fre-
quently prescribed ACEi than ARB therapy. CONLUSIONS:
ARBs were prescribed cautiously in the UK and ARB prescrib-
ing patterns altered over time as new safety and effectiveness evi-
dence emerged.
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OBJECTIVES: To describe the role of general practitioners (GPs)
in the initial management of women with UI in 4 European coun-
tries with different health care systems. METHODS: Cross-
sectional community postal survey of 2,953 community-dwelling
women with UI in France, Germany, Spain and the UK.
RESULTS: There was an overall response rate of 53% (n =
1573). Forty eight percent had discussed their UI with a doctor.
More women discussed UI in France and Germany than in the
UK and Spain. The patient usually raised the issue, during con-
sultations for some other reason. Fear of, or actual deterioration
in UI was the most important reason for discussing UI. Overall
52% of incontinent women ﬁrst discussed their UI with a GP
and almost a third of women reported having all their UI dis-
cussions in a GP setting. Twenty nine per cent of women reported
that GPs had either recommended treatment or monitoring of
their condition before beginning treatment and 24% reported
